Evidence map›Paper›PMID 33346631›Full record

ArticleACS chemical neuroscience2021

SAR Matrices Enable Discovery of Mixed Efficacy μ-Opioid Receptor Agonist Peptidomimetics with Simplified Structures through an Aromatic-Amine Pharmacophore.

Sean Henry, Jessica P Anand, Ashley C Brinkel, Douglas M McMillan, Jack J Twarozynski, Christian E Loo, John R Traynor, Henry I Mosberg

Abstract read
In one paragraph

Article in ACS chemical neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sean HenryDepartment of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States.
Jessica P AnandDepartment of Pharmacology, Medical School, University of Michigan, Ann Arbor, Michigan 48109, United States.
Ashley C BrinkelDepartment of Pharmacology, Medical School, University of Michigan, Ann Arbor, Michigan 48109, United States.
Douglas M McMillanDepartment of Pharmacology, Medical School, University of Michigan, Ann Arbor, Michigan 48109, United States.
Jack J TwarozynskiDepartment of Pharmacology, Medical School, University of Michigan, Ann Arbor, Michigan 48109, United States.
Christian E LooDepartment of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States.
John R TraynorDepartment of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States.
Henry I MosbergDepartment of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States.ORCID 0000-0002-4107-8870

Funding

Development of Mixed Function Opioid Peptides and PeptidomimeticsR01DA003910 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MOSBERG, HENRY ISAAC · 1985 to 2017
$9.0M
Allosteric Modulation of the Mu-Opioid ReceptorR37DA039997 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI TRAYNOR, JOHN R. · 2015 to 2024
$6.4M
NIDA Training Program in Neuroscience-Administrative SupplementT32DA007281 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Shelly Beth Flagel · 1995 to 2026
$5.7M
Supplement for CSULB Maximizing Access to Research Careers (MARC) UNDERGRADUATE STUDENT TRAINING IN ACADEMIC RESEARCH (U-STAR)T34GM008074 · NIGMS · CALIFORNIA STATE UNIVERSITY LONG BEACH · PI NARAYANASWAMI, VASANTHY · 1985 to 2022
$4.6M
Development of Long Lasting Stable Fentanyl Antagonist to Reverse Opioid OverdoseR21DA051732 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ANAND, JESSICA PRIYA · 2020 to 2021
$429k
Examining Novel Fentalogs: Pharmacological Characteristics and ReversibilityR03DA048129 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ANAND, JESSICA PRIYA · 2019 to 2020
$156k
NIDA NIH HHS R01 DA003910NIDA NIH HHS R03 DA048129NIDA NIH HHS R21 DA051732NIDA NIH HHS R37 DA039997NIDA NIH HHS T32 DA007281NIGMS NIH HHS T34 GM008074
6 · The paper itself

Abstract

We previously described the development of potent μ-opioid receptor (MOR)-agonist/δ-opioid receptor (DOR)-antagonist peptidomimetic ligands as an approach toward effective analgesics with reduced side effects. In this series, a tetrahydroquinoline (THQ) or substituted phenyl is employed to link two key pharmacophore elements, a dimethyltyrosine amino acid and typically an aromatic pendant. Using new and previously reported analogues, we constructed a structure-activity relationship (SAR) matrix that probes the utility of previously reported amine pendants. This matrix reveals that the MOR-agonist/DOR-antagonist properties of these ligands do not change when a tetrahydroisoquinoline (THIQ) pendant is used, despite removal of substituents on the core phenyl ring. Based on this observation, we retained the THIQ pendant and replaced the phenyl core with simpler aliphatic chain structures. These simpler analogues proved to be potent MOR-agonists with high variability in their effects at the DOR and the κ-opioid receptor (KOR). These data show that the amine of the THIQ pendant may be a novel pharmacophore element that favors high MOR-efficacy, whereas the aromatic ring of the THIQ pendant may produce high MOR-potency. Combined, the two pharmacophores within the THIQ pendant may be a structurally efficient means of converting opioid peptides and peptidomimetics into potent and efficacious MOR-agonists.

Indexed as

PeptidomimeticsAminesAnalgesics, OpioidReceptors, Opioid, deltaReceptors, Opioid, kappaReceptors, Opioid, muStructure-Activity RelationshipAminesAnalgesics, OpioidPeptidomimeticsReceptors, Opioid, deltaReceptors, Opioid, kappaReceptors, Opioid, mubifunctional ligandspeptidomimeticsstructure−activity relationshipδ-opioid receptorκ-opioid receptorμ-Opioid receptor

Identifiers

PMID33346631
PMCPMC9923772

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.